-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KRBDWdq2uxKDzFqoLXJ6V37AvKEvA08sITR4A7uL/fgDcym5xD9O+1Wxenpb2i1G
 i2ALufB6FY7dJaMmDwFIgA==

<SEC-DOCUMENT>0001188112-08-003105.txt : 20081110
<SEC-HEADER>0001188112-08-003105.hdr.sgml : 20081110
<ACCEPTANCE-DATETIME>20081110172045
ACCESSION NUMBER:		0001188112-08-003105
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20081110
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20081110
DATE AS OF CHANGE:		20081110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT [3663]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		081176899

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t63993_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
  <head>
    <title>t63993_8k.htm</title>
<!-- Licensed to: tsf-->
<!-- Document Created using EDGARizer 4.0.6.1 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON,
D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">FORM
8-K</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
REPORT</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT
TO SECTION 13 OR 15(d) OF THE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
of report (Date of earliest event reported): November 10, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied
DNA Sciences, Inc</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
Name of Registrant as Specified in Charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or Other Jurisdiction</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
      Incorporation)</font></div>
              </td>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">002-90539</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
      File Number)</font></div>
              </td>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">59-2262718</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
      Employer</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification
      No.)</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25
Health Sciences Drive, Suite 113</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stony
Brook, New York 11790</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of Principal Executive Offices) (Zip Code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">631-444-
8090</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
telephone number, including area code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
Applicable</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
Name or Former Address, if Changed Since Last Report)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: silver" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
8.01.&#160;&#160;Other Events.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A copy of
the letter to stockholders of Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) in
connection with the Company&#8217;s solicitation of proxies for the 2008 annual
meeting of stockholders is attached to this Current Report as Exhibit
99.1.&#160;&#160;The Company will post this letter on its website at <font style="DISPLAY: inline; FONT-STYLE: italic">www.adnas.com</font> after the
filing of this Current Report.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Forward-Looking
Statements</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
letter to stockholders in connection with the Company&#8217;s solicitation of proxies
for the 2008 annual meeting of stockholders may contain statements of a
forward-looking nature relating to future events.&#160;&#160;These
forward-looking statements are subject to the inherent uncertainties in
predicting future results and conditions.&#160;&#160;These statements reflect
the Company's current beliefs, and a number of important factors could cause
actual results to differ materially from those expressed in the letter to
stockholders in connection with the Company&#8217;s solicitation of proxies for the
2008 annual meeting of stockholders.&#160;&#160;Please see the Company's Annual
Report on Form 10-KSB for the fiscal year ended September 30, 2007, the
Company&#8217;s reports on Form 10-QSB for the quarters ended December 31, 2007, March
31, 2008 and June 30. 2008, and subsequent filings, filed with the Securities
and Exchange Commission, for a more detailed discussion of the risks and
uncertainties associated with the Company's business, including but not limited
to the risks and uncertainties associated the Company&#8217;s history of losses, need
for additional financing and other significant factors that could affect the
Company's actual results.&#160;&#160;Except as otherwise required by Federal
securities laws, Applied DNA Sciences, Inc., undertakes no obligation to update
or revise these forward-looking statements to reflect new events or
uncertainties.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Additional
Information</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
reference to the website <font style="DISPLAY: inline; FONT-STYLE: italic">www.adnas.com</font> has been
provided as a convenience, and the information contained on such website is not
incorporated by reference into this Form 8-K.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
9.01 Financial Statements and Exhibits</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(d)</font></div>
              </td>
              <td valign="top" width="85%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits.</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="left" valign="top" width="85%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.1</font></div>
              </td>
              <td align="left" valign="top" width="85%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter
      to stockholders in connection with the Company&#8217;s solicitation of proxies
      for the 2008 annual meeting of
stockholders.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: silver" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Applied
      DNA Sciences, Inc.</font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
              </td>
              <td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ James A. Hayward</font></font></div>
              </td>
              <td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="22%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James
      A. Hayward</font></div>
              </td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="22%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></div>
              </td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
November 10, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: silver" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
INDEX</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      No.</font></div>
              </td>
              <td align="left" valign="top" width="90%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.1</font></div>
              </td>
              <td align="left" valign="top" width="90%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter
      to stockholders in connection with the Company&#8217;s solicitation of proxies
      for the 2008 annual meeting of
stockholders.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title>ex99-1.htm</title>
<!-- Licensed to: tsf-->
<!-- Document Created using EDGARizer 4.0.6.1 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="TEXT-ALIGN: center">
      <hr style="COLOR: black" align="center" noshade size="1" width="100%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="TEXT-ALIGN: right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 99.1</font></div>
      <div>&#160;</div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="img.jpg" alt="graphic"></font></td>
              <td width="50%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: times new roman">Stockholder
      Newsletter - November 2008</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td width="41%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TO OUR
      STOCKHOLDERS,</font></td>
              <td width="11%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="justify" width="48%" style="BORDER-RIGHT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-LEFT: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: times new roman">APDN
      Highlights</font></div>
              </td>
            </tr>
            <tr>
              <td width="41%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td width="11%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="justify" width="48%" style="BORDER-RIGHT: black 2px solid; BORDER-LEFT: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify">&#160;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="2" valign="top" width="41%">
                <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the world today,
      our DNA authentication solutions are more relevant than ever. In 2008
      global markets suffered from massive increases in product tampering, IP
      infringements, adulterations and outright counterfeits. The victims are
      consumers, corporations and governments alike. The impact is not virtual,
      but measured in lives lost, stolen revenues, devalued brands, diminished
      quality and heightened insecurity. <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">We believe
      Applied DNA Sciences offers the most viable authentication solutions
      available to curb these threats. </font>The marketplace is beginning to
      hear us; our product offerings are gaining traction each month; our
      quality promise has been tested and realized; our revenues are growing
      each quarter. We have reported our fourth consecutive quarter of revenues,
      with our last three quarters averaging 30% growth quarter-over-quarter.
      This year, we have manufactured over 1000 unique SigNature&#8482; DNA markers
      for a broad spectrum of customers; many of those DNA sequences have the
      potential to generate annuities for years to come. Applied DNA (&#8220;APDN&#8221;)
      has begun to deliver commercial solutions, and our investors and society
      should benefit.</font></div>
                <div>&#160;</div>
                <div><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2">Applied
      DNA in the Global Marketplace</font></font></div>
                <div>
                  <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Applied DNA
      story is largely intertwined with a global marketplace, driven primarily,
      by the enhanced need for safety and security. <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Each time a
      product changes hands in its path to the market, mistrust in the
      authenticity of the product increases. </font>The anti-counterfeiting
      market has been largely shaped by the media, by reporting on contaminated
      or adulterated goods, rather than the ways to authenticate genuine
      products in the supply chain in order to ensure consumer confidence. Most
      of our competitors emphasize only the deterrent value of their technology.
      Going beyond deterrence, APDN&#8217;s strength is sustained from the front end -
      marking the physical product, to the back end - <font style="DISPLAY: inline; FONT-WEIGHT: bold">authentication of a forensic
      DNA sequence that uniquely identifies a single
      item.</font></font></div>
                </div>
              </td>
              <td width="11%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="left" width="48%" style="BORDER-RIGHT: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-BOTTOM: black 2px solid">
                <div style="TEXT-INDENT: 9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Four
      consecutive quarters of increased revenues</font></font></font></div>
                <div style="TEXT-INDENT: 9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Over
      1,000 unique SigNature DNA markers developed for customers in multiple
      global markets</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Broadened
      product lines comprised of SigNature DNA, BioMaterial Genotyping,
      BioActive Ingredients build upon our strategy of diversified revenue
      sources with managed risk concentration and shortened sales
      cycles</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Improved
      detectability and authentication processes for DNA providing better in
      field recovery and controls</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Auditable
      processes and controls implemented throughout the company to support
      authentication and security to our
      customers</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expanded
      patent and trademark portfolios which will form the basis for added value
      through future licensing revenue
      opportunities</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Growing convergence of public
      awareness of APDN&#8217;s DNA Authentication technologies as a credible means to
      protect genuine products and consumer safety and well
      being</font>.</font></font></font></font></div>
                <div style="MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt" align="left">&#160;</div>
              </td>
            </tr>
            <tr>
              <td width="11%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td width="48%">
                <div style="TEXT-ALIGN: justify">&#160;</div>
                <div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">This year, APDN
      broadened its commercial scope to best position us to ultimately capture
      the lion&#8217;s share of the opportunities available to DNA-based
      authentication. SigNature DNA, our central platform that uses botanically
      derived genomic DNA sequences as proof of originality was deployed in a
      new industry vertical, cash-in-transit. We have increased our penetration
      into the markets for secure inks, labels, event ticketing, and branding in
      general.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>&#160;</div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 1</font></div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: silver" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><img src="img.jpg" alt="GRAPHIC"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
    </div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%">
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One of our most
      dramatic developments has been our entry into the world of genotyping
      commercial products by analyzing the DNA content that may be found in
      naturally derived products. The sales cycle for BioMaterial Genotyping is
      shorter than for SigNature, and it is less expensive for our customers but
      provides attractive margins to APDN. While our point of entry was focused
      on biologically derived textiles, the range of applications represents a
      global market with over $1 trillion in annual sales and includes foods,
      wines, coffee, nutritional supplements, natural products in personal care
      and biological drugs. <font style="DISPLAY: inline; FONT-WEIGHT: bold">We
      believe the combination of SigNature DNA and BioMaterial Genotyping covers
      the total authentication market.</font> Their combination represents an
      important strategic development since both platforms are applicable to
      multiple industry verticals, provide diverse revenue streams, lower risk
      concentration and shorten our average sales cycle.</font></font></div>
              <div style="TEXT-ALIGN: justify">&#160;</div>
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As we completed our
      initial supply contracts, we have worked to shorten the sales cycle. Our
      initial projects all represented customized solutions that required
      complete knowledge of a customer&#8217;s business process. With those
      experiences under our belts, APDN has been able to develop more
      market-ready product formats, <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">enabling
      faster SigNature price quotations and more concise product
      cycles.</font></font></font></div>
              <div style="TEXT-ALIGN: justify">&#160;</div>
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In a further effort
      to secure faster revenue, less dependent on security issues, we have taken
      advantage of the manufacturing tools we use to generate DNA markers.
      Fermentation is the method of choice for producing DNA at large scale. Our
      management team has used fermentation in prior positions to manufacture
      biological drugs and active ingredients for skin care. The latter industry
      offers a rapid path to market, 3-5 year sales annuities once the
      ingredient has been used by a marketed brand, and low commercial risk.
      More importantly, this revenue stream for <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">BioActive
      Ingredients shortens our time to profitability and lessens the company&#8217;s
      historic dependence on fund-raising.</font></font></font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%">
              <div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
                <div style="TEXT-INDENT: 9pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2">Recession
      Resistance</font></font></div>
                <div>
                  <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Segments of the
      personal care industry exhibit better resistance to economic
      recession.</font></div>
                </div>
              </div>
              <div>&#160;</div>
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We anticipate that
      the BioActive Ingredients business will grow in 2009, and provide us with
      revenues in the near term. We also anticipate that the impact of global
      counterfeiting on brands will grow during times of economic stress as
      consumers strive to save money and counterfeiters broaden their target
      scope. We believe our ability to provide customers with products and
      services in both brand security and ingredient development is unique, and
      sets us apart from other companies.</font></div>
              <div>&#160;</div>
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APDN is working to
      establish a sales network with agents in New York, Chicago, California,
      and recently, in Asia. Our efforts provided immediate gratification, with
      our ingredients now used by several leading global brands for whom we are
      supplying repeat orders. In addition to purchasing our Bioactive
      Ingredients, these customers have demonstrated longer-term interest in
      using our authentication platforms to protect or enhance their
      brands.</font></div>
              <div style="TEXT-ALIGN: justify">&#160;</div>
              <div style="TEXT-ALIGN: justify">
                <div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">The&#160;Transformative&#160;Power&#160;of&#160;DNA</font></font></div>
                <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The transformative
      power of DNA is realized through the enhanced detectability and
      authentication systems developed at APDN as <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">DNA markers
      can now be screened for in the field and authenticated in the
      lab.</font></font></div>
                <div style="TEXT-ALIGN: justify">&#160;</div>
                <div style="TEXT-ALIGN: justify">
                  <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have successfully
      developed proprietary methodologies to covalently link our DNA markers to
      optical reporters that will enable real-time screening of products that
      can be read by commercially available handheld devices. We have developed
      proprietary, patent pending technologies for enhancing the detectability
      of DNA, in some cases, we believe as much as 1000 fold better than methods
      used by the FBI. We now offer a full range of detection options from
      instant rapid screening to more detailed forensic
      authentication.</font></div>
                </div>
              </div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 2</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right"><img src="img.jpg" alt="GRAPHIC"></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smiths
      Detection and Sensor Cat</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our
      strategic partnerships with Smiths Detection (SMIN:LSE) and the Sensor Cat
      at the University at Stony Brook, to customize hand-held forensic
      authentication devices further differentiates us from all other
      competitors. Our agreement with Smiths details the development of a
      mechanism for in-field, fully-forensic DNA authentication with a handheld,
      battery-powered PCR-based device that will confirm authenticating
      sequences in roughly 10 minutes. With the Sensor CAT, we have successfully
      completed Phase 1 development of a proprietary new instant detection
      device that is being partially funded through a grant to APDN. This new
      detector offers greater sensitivity while still being able to reliably
      operate in harsh environments in the field. This next generation of
      instant detectors is designed to thwart anyone trying to counterfeit,
      divert or pirate products marked with SigNature DNA. Combined with our
      forensic authentication tools, this new reader will complete the next
      generation of our SigNatureDNA platform.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DNA
      in Government</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      have seen how CEOs of Fortune 100 companies or Homeland Security officials
      respond to DNA - not purely as an added cost or as a forensic tool at a
      crime scene, but as strategic approach to the way they protect their own
      interests. This shift is significant and real, as evidenced
      by:</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
      recent signing of the PRO-IP Act which toughens prosecution and mandatory
      sentencing for convicted counterfeiters, brings more awareness to the
      security industry and our company.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On
      October 2, 2008, Business Week published its lead article on &#8220;Dangerous
      Fakes&#8221; indicating that even the United States military is facing a
      &#8220;growing threat of potentially fatal equipment failure-and even foreign
      espionage - because of counterfeit computer components used in warplanes,
      ships and communication networks&#8230;. Senior Pentagon officials publicly play
      down the danger, but government documents, as well as interviews with
      insiders, suggest possible connections between phony parts and
      breakdowns.&#8221;</font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long
      term, we are working towards developing government contracts to
      incorporate SigNature DNA into homeland security and government
      applications. Our dialog with government and dedicated security
      institutions in the US, UK, Europe and Australia has intensified,
      signaling the need for DNA-based forensic methodologies that can protect
      national security interests. We have begun making inroads, with recent
      project proposals including using SigNature DNA for credentials, driver&#8217;s
      licenses, border control, national trade protection and even ransom
      money.</font></div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As
      we understand that attaining government contracts is a timely endeavor, in
      the short term, we are also focused on developing commercial relationships
      to generate revenues and sustain the company.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DNA&#160;for&#160;Secure&#160;Documents&#160;and&#160;Printing</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For
      the last two years, APDN has worked with a number of strategic partners to
      elevate the value added by incorporating our DNA in inks, varnishes,
      adhesives etc., that can now be used for secure documents and
      printing.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Printcolor</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Since
      June 2008, we have been collaborating with PrintColor, our Swiss-based
      security ink manufacturer, to enhance security inks with SigNature DNA.
      Many potential customers throughout Europe and the UK are testing our
      SigNature DNA inks to protect government documents, auto parts, luxury
      goods and consumer products. The cash-in-transit industry requested our
      help to improve the inks used to mark cash stolen from ATMs or transport
      boxes. Together with PrintColor, we have developed AzSure. We are
      optimistic that AzSure can provide advantages to governments and industry
      alike, and we plan an aggressive launch in early 2009.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IIMAK</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our
      collaboration with IIMAK has produced a portfolio of SigNature
      DNA-containing thermal transfer ribbons
  (TTR).</font></div>
              </div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 3</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: left"><img src="img.jpg" alt="GRAPHIC"></div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%">
              <div style="MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">These products will
      allow government agencies to verify the authenticity of secure documents
      and credentials, and provide industry verticals to protect products from
      point-of-origin through point-of-sale by printing labels, hang tags, and
      event tickets with customized SigNature DNA TTR. We expect initial sales
      in 2009. Following our successful scale-up with IIMAK, we have now
      extended our experience in secure printing to include marking the
      cartridges of laser printers with SigNature DNA, and we are exploring the
      potential for partners now.</font></div>
              <div>&#160;</div>
              <div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DNA
      in Commerce</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">After
      two years of selling experience, we believe it is clear this platform can
      impact world trade and protect consumers. It is also clear is that the
      sales cycle varies with the size and complexity of the customer. SigNature
      DNA is applicable to many industry verticals and provides our company with
      diverse revenue streams with little risk concentration.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Authentication
      issues plague the global economy and are no longer considered the
      exception, but rather the rule. The common theme that has emerged is that
      the &#8220;tried and true&#8221; technologies that have been around for years like
      holograms and bar codes all can be copied, and the counterfeiting problem
      is now relevant to, by some estimates, as much as 10% of global
      trade.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
      today&#8217;s complex global marketplace, a brand that can positively identify
      itself against all fakes is a brand that can command the market, and at a
      premium price. <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">Authentication
      is the essential competitive feature that a brand can add to increase its
      value going forward. </font>With authentication, which we believe can only
      truly be offered with DNA, a brand can be more than a trademark, it can be
      a <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">trust</font>mark.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">

                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Generating
      Revenues</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SigNature
      DNA</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">This
      is the technology upon which the company was originally founded. It
      involves the creation of a unique botanical DNA &#8220;external&#8221; marker that is
      encrypted, then added to an ink, varnish,</font></div>
                </div>
              </div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">adhesive,
      thread or to the product itself and subsequently authenticated. While the
      marketplace does not suffer from a shortage of lower-technology security
      solutions, our SigNature DNA has strengthened its potential for market
      leadership: our markers are more unique, <font style="DISPLAY: inline; FONT-WEIGHT: bold">resistant to copying, stable
      over time and more &#8220;forensic&#8221; since DNA is well accepted by the courts
      globally.</font></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thanks
      in large part to the funds raised, including my personal investment
      totaling $1.35 million, APDN scaled up its ability to manufacture DNA
      markers to a capacity capable of producing tens of millions of marks per
      batch. Simultaneously, we have increased our standards for Quality Control
      to the equivalent used in the manufacture of drugs under cGMP, in
      compliance with forensic quality control methods and secure database
      management systems that will pass audit.</font></div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SigNature
      DNA, launched in 2005, is starting to generate revenues for the company
      based on our DNA markers embedded in a range of inks, varnishes, and other
      substrates. Our DNA often has to be rigorously validated within different
      chemistries, temperatures, pH levels, and other harsh conditions. We
      believe that our technology is more resilient than many other competitive
      technologies.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unique
      SigNature DNA sequences have been successfully commercialized and
      incorporated in a number of product applications such as security labels
      for Rhodia&#8217;s Jaguar line of ingredients, and most recently, for
      cash-in-transit in the UK, AzSure DNA ink, event tickets, as well as
      textiles and apparel.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash-In-Transit</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Through
      the work we conducted with security inks, laser toners and thermal
      transfer ribbons, we were able to easily incorporate our DNA markers in
      cash degradation ink that is used in the Cash-In-Transit industry. This
      solvent-based ink is used to mark cash if the cash box is compromised and
      therefore must have the ability to penetrate the cash rapidly and
      permanently. We have conducted hundreds of CIT DNA deployments to ensure
      that even with the most strenuous attempts to wash out the ink, the DNA
      still persists in the note itself, and can be forensically and reliably
      extracted.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 4</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right"><img src="img.jpg" alt="GRAPHIC"></div>
    <div>
    </div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
      February 2008, we announced our first shipment of SigNature DNA markers to
      the cash-in-transit industry in the UK, and we have since shipped multiple
      additional orders to this customer. It is an area that we will continue to
      expand our sales and marketing efforts as we believe the use of our
      SigNature DNA markers is proving to be much more resilient and detectable
      than other competing products. In September 2008, we introduced our
      SigNature DNA system to the Metropolitan Police in London. The police
      responded favorably to our presentation and remain in contact with us as
      our CIT business grows.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AzSure
      DNA Ink Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A
      UK client requested that we help them improve upon their existing ink
      system. We anticipate that our newly-developed AzSure system will provide
      the global CIT industry with a substantially improved product. We believe
      the unique visible and fluorescent <font style="DISPLAY: inline; FONT-WEIGHT: bold">blue</font> signature of our
      highly substantive dye/DNA system distinguishes AzSure from all other dyes
      used within the CIT industry. We believe the initial tests indicate that
      the penetration and wash-out resistance is comparable or in some cases
      significantly better than any existing system. In addition to the British
      Pound, we have also conducted testing of AzSure on US currency, and Euros
      to ensure reliability on different paper substrates. We will continue to
      execute on sales for both our SigNature DNA markers and AzSure DNA Ink to
      service global markets.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Event
      Ticket Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      are currently working to bring to closure a number of event ticketing
      opportunities that we have been developing over the past year. One such
      project involves the inclusion of DNA as a forensic ticket authentication
      solution for a global sports event organization. In preparation for this
      event, we have successfully piloted our SigNature DNA markers and
      chemically-linked them to an invisible, covert ink that is used by a
      global ticket manufacturer. Based on the success of this program, we are
      now working on piloting our SigNature DNA markers at selected events that
      will be used to verify credentials and tickets prior to the events as well
      as during and after the event. The purpose of our
      multi-staged</font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">authentication
      program is to conduct statistical sampling of the event to verify if any
      systematic counterfeiting has occurred. It is anticipated that after the
      completion of the pilots we will ramp up our efforts to provide <font style="DISPLAY: inline; FONT-WEIGHT: normal">DNA marking and
      authentication services to a much larger cross-section of events.</font>
      We believe the marketing and publicity surrounding these events will also
      help to increase awareness about our SigNature DNA platform as we continue
      to execute and grow sales in this market.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Textiles
      and Apparel Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One
      of the verticals that we are very excited about is the application of
      SigNature DNA to mark textiles (fiber, yarn, fabric), as well as apparel
      (woven and non-woven labels, care labels, hang tags and garments). Our
      work with Idaho National Labs to validate the use of DNA thread helped to
      spearhead our efforts in the past year. Through our project with Supima,
      we have demonstrated that <font style="DISPLAY: inline; FONT-WEIGHT: bold">DNA can be applied to cotton
      fiber, yarn and now finished fabrics.</font> Based on the strength of the
      data collected, we were able to initiate dialogue with the Textile Centre
      of Excellence associated with Leeds University, as a path to introduce our
      technology to the larger European textile community. As part of this
      program in Yorkshire, the European Union has requested APDN to establish a
      pan-European authentication center constructed in part with public
      funds.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
      collaboration with the Textile Centre of Excellence and Yorkshire Forward
      (the economic development agency for northern England), APDN is DNA
      marking yarn, woven fabrics, threads, labels and finished garments. We
      have formed commercial liaisons with Yorkshire textiles yarn
      manufacturers, weavers, finishers, woven and non-woven labelers and
      garment manufacturers. The initial funding for this project is &#163;50,000,
      with the potential for more significant funding upon its successful
      completion in December 2008. APDN serves on the board of the project
      advisory group that will advise on the second phase of this project slated
      to begin in early 2009, which may include APDN&#8217;s BioMaterial Genotyping
      program for wool.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 5</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: left"><img src="img.jpg" alt="GRAPHIC"></div>
    <div style="TEXT-ALIGN: left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supima&#174;
      Cotton Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our
      relationship with Supima resulted in a groundbreaking feasibility contract
      that was successfully completed within the year. We have extended our
      genotyping of finished fabrics or garments to the genetic analysis of
      single fibers. This development permits the authentication of more complex
      fabrics such as towels which may be comprised of multiple sources of
      cotton. Supima is now introducing APDN to many of its licensees, ranging
      from multinational brand owners, manufacturers to retailers. We are
      working with Supima to require that all licensees (over 200) utilize
      APDN&#8217;S BioMaterial Genotyping testing each time the product changes hands
      at any point in the manufacturing process: fiber to yarn, yarn to fabric,
      fabric to garment, garment to retailer. <font style="DISPLAY: inline; FONT-WEIGHT: bold">We have several authentication
      programs in pilot testing.</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      believe the Supima Cotton Authentication program is unique to APDN. For
      the first time ever, we were able to differentiate Pima cotton (<font style="DISPLAY: inline; FONT-STYLE: italic">G. barbadense</font>) from
      Upland cotton (<font style="DISPLAY: inline; FONT-STYLE: italic">G.
      hirsutum</font>) in a genetic test we trademarked as FiberTyping. We also
      developed our own genetic assay which allows for differentiation between
      varietals of Pima cotton grown in different regions of the world. We
      trademarked this as PimaTyping. Supima cotton is American Pima cotton and
      it is important to the Supima organization to have a test that can
      differentiate not only Pima from Upland cotton, but also American Pima
      cotton from other Pima cottons from around the world.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      believe the value of the Supima project is in demonstrating for the first
      time an authentication tool that can be applied throughout the <font style="DISPLAY: inline; FONT-WEIGHT: bold">global cotton industry</font>
      from cotton growers, mills, wholesalers, distributors, manufacturers and
      retailers through trade groups such as Supima as well as government
      agencies, like the FTC, Department of Commerce and
      USDA.</font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USDA</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      are working with the US Department of Agriculture (USDA) which is looking
      for a way to mark and identify US grown cotton as it moves from the field
      through the manufacturing process to retail outlets, crossing multiple
      borders in the process. The ultimate goal of this collaboration is the
      development of a protocol that will definitively identify US grown cotton
      using either SigNature DNA, BioMaterial Genotyping or a combination of the
      two technologies. We believe this could have significant potential
      applications for the <font style="DISPLAY: inline; FONT-WEIGHT: bold">enforcement of trade quotas in
      the US </font>and beyond, and for <font style="DISPLAY: inline; FONT-WEIGHT: bold">legislated quality improvement
      </font>within the industry.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Wool
      Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Based
      on the Supima Cotton program and our connection to the Textile Centre of
      Excellence in Yorkshire, we recognized that the next natural area for us
      to authenticate is wool, slated to begin in early 2009. Recently the
      European Union has increased the funding for this portion of the program,
      another government relationship that is being developed.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Based
      on the unique properties of wool, we believe that it is feasible to
      develop proprietary methods to identify wool DNA in finished fabrics, as
      well as in yarn and fiber. We conducted some initial tests to demonstrate
      that the addition of SigNature DNA to fine baby cashmere fabric can be
      authenticated with no alteration to the quality of the fabric. This fabric
      is been submitted for further independent testing by a number of
      well-established, prestige design houses in
  Italy.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 6</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right"><img src="img.jpg" alt="GRAPHIC"></div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have also had initial dialogue with the Australian Wool Innovation group
      and Wools of New Zealand, the two largest exporters of wool, including
      Superior Merino wool which is known for extra fine quality. To date, there
      has not been any genetic tests developed to authenticate wool DNA from
      finished fabrics and we believe this is a potentially important area that
      could produce significant opportunity for revenue.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wine
      Authentication</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      August 2008, we announced our plans to begin applying our BioMaterial
      Genotyping expertise to the genotyping of wine. This would allow us to
      identify wine based on the varietal of grape and the region it is grown
      in. Wine counterfeiting has become more prevalent throughout the world,
      and the need to verify the wine itself is becoming the only way to
      differentiate a wine that is genuine or not. As it happens, APDN&#8217;s
      headquarters are in close proximity to a cluster of wineries located in
      the north east end of Long Island. In addition, New York State Senator
      Kenneth LaValle recently announced a New York State Initiative to
      establish an Agricultural Consumer Science Center on Eastern Long Island
      in the burgeoning wine district. APDN Sciences is collaborating with New
      York State to make its technologies and authentication services available
      to regional wineries through this Center.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Management</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our
      management team is focused on building long term stockholder value by
      building competitive products and growing profitable sales as quickly as
      we can. We are deeply experienced in the construction of effective patent
      portfolios. With each new technical achievement, our team carefully
      evaluates the potential for patent protection. In 2008, we have added
      several new applications which could eventually bring licensing
      revenue.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I
      am grateful to the commitment and efforts of all our employees. Over the
      course of the year, we have hired additional employees focused on the
      delivery and execution of all of our revenue generating, commercial
      programs in line with quality standards that will pass
      audit.</font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      continue to strive to strengthen our Board, with the goal of adding
      additional financial and business acumen to further enhance the ability of
      APDN to succeed. In the past year we promoted Kurt Jensen, M.Sc (Cand
      Merc.) from the position of Comptroller to Chief Financial Officer and
      Corporate Officer of the company. Mr. Jensen has played an instrumental
      role in bringing the company into compliance with respect to SEC filings
      and accounting issues and has resolved many of the outstanding legal
      issues that the company had inherited from previous management. Mr. Jensen
      has also implemented fiscally conservative policies to manage cash flows
      and lower operating costs.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Getting
      Noticed</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      are currently planning multiple initiatives to heighten investor and
      general public awareness of APDN&#8217;s products and competitive positioning in
      targeted vertical markets. Our exposure is improving as evidenced by the
      increase in requests for comments, quotes, interviews, presentations and
      articles by APDN. In response to this, we have produced high quality
      marketing, sales and investor collateral supported by video demonstrations
      used for sales and investor meetings.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      the past year we have been covered in numerous media outlets including
      larger features in local and national press. We have also been invited to
      present at numerous conferences sponsored by government, different
      industry verticals and consortiums. We will continue to work to expand the
      recognition of our company and technology throughout our target industries
      as well as trade groups, potential customers, partners and investors. We
      are planning to update our website to incorporate all the new aspects of
      our business and we will continue to pursue all opportunities for coverage
      of the company.</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 7</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: silver" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: left"><img src="img.jpg" alt="GRAPHIC"></div>
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">This
      year we worked with Cameron Associates and SmallCapNetwork.com to enhance
      our Investor Relations, in addition to maintaining relationships with
      prior IR firms. We recognize the need to improve our Investor Relations
      activities and will continue to increase our efforts as our resources
      permit. Recent efforts resulted in our invitation to present at the annual
      Homeland Security Investor conference in Washington, DC, sponsored by
      Imperial Capital.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Looking Ahead</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      believe in the strength of our DNA Authentication platforms and our
      growing BioActive Ingredients business and we are confident in our
      strategy as we get closer to profitability. Specifically, in the short
      term we are focused on growing and executing on sales, without expanding
      operating costs, so that we cross the profitability barrier as quickly as
      possible. We remain committed to tight fiscal governance and anticipate
      continued quarterly revenue growth over the next year as we build on the
      strengths of our core businesses and partnerships.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We
      are confident that many of the positive developments that we have made
      will come to fruition in 2009. We have made significant progress toward
      our goals and we believe our vision and strategy will take us there, as
      demonstrated by our achievements thus far.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">Your ongoing support is instrumental to the long-term health
      and success of our company. We wish to thank you for your continued
      support and commitment to Applied DNA
Sciences.</div>
                </div>
              </div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">The
      statements made by Applied DNA Sciences, Inc. may be forward-looking in
      nature and are made pursuant to the safe harbor provisions of the Private
      Securities Litigation Reform Act of 1995. Forward-looking statements
      describe the Company&#8217;s future plans, projections, strategies and
      expectations, and are based on assumptions and involve a number of risks
      and uncertainties, many of which are beyond the control of Applied DNA
      Sciences, Inc. Actual results could differ materially from those projected
      due to changes in interest rates, market competition, changes in the local
      and national economies, and various other factors detailed from time to
      time in Applied DNA Sciences&#8217; SEC reports and filings, including our
      Registration Statement on Form S-1 as amended and Annual Report on Form
      10-KSB, filed on January 15, 2008, our subsequent Quarterly Reports on
      Form 10-QSB, and our Current Reports on Form 8-K. The Company undertakes
      no obligation to update publicly any forward-looking statements to reflect
      new information, events or circumstances after the date
      hereof.</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%">
              <div style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="img1.jpg" alt="graphic"></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%">
              <div style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25 Health Sciences
      Drive</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ James A.
      Hayward</font></td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stony
      Brook, NY 11790</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A.
      Hayward</font></td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%">
              <div style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">t
      631-444-6370&#160;&#160;&#160;f 631-444-8848</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="48%">
              <div><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November
      2008</font></div>
            </td>
            <td width="4%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            <td valign="middle" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">info@adnas.com
      &#8226; www.adnas.com</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Stockholder
Letter - November 2008 - Page 8</font></div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!7`3H#`2(``A$!`Q$!_\0`
M'``!``(#`0$!``````````````8'`P4(!`(!_\0`/A```0,#`P(#!P($`P<%
M`````0(#!``%$082(0<Q$T%1%"(R87&!D0BA%2-"4B22P18S8G*"L?`7.':B
ML__$`!L!`0`#`0$!`0`````````````$!08#`@<!_\0`+1$``@("`0,"!`4%
M``````````$"`P01(04Q01)1%)&AP2(R87&Q!A,5@='_V@`,`P$``A$#$0`_
M`.J:4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"
ME*4`I2HSU'U(=*:3EW)M(7)X:82KMXBNQ/R')^U>ZZY6S4(]V>+)JN+G+LC:
MWB^VJS)2JZW&+$W?"'G0DJ^@[FL=HU%9KRM2+5=(<MQ/)0TZ%*`]<=ZXXN4^
M7<YKLNX2')$ET[EN.*R3_P">E8XDEZ'):D175LOM*"D.(.%)(\P:TR_IV/HY
MG^+Z&?\`\]+U_D_#]3N"J@UAUG;LNH9-MM]K3,;BK+3KJWMFY8.%!(`/`[9_
M:I;TGU4YJS2B)4K;[='66'\<!2@`0K'S!'WS4)UKT:7==0RKC:[DQ&9EN%U;
M3Z3[KBCD[2.X))..,9JKPZL>J^5>;X_?O_HL<JV^VF,\3S^WW+-L^I[9<M,Q
MKZ9#<6"\C<52%I0$$$@I)SC(((K:PI<:=&1(A2&9$=?*76EA:5?0CBN3-67P
M.V"T:;98#*;.MY#RD/>(V^X5?&DX[?%_FXJU_P!-0/\``+P?'"D^U)PSGE'N
M?%]^W_377+Z4J*'?OSPOTWQS]3EB]3=URIUXY?ZZY_X7%2L#,V*\^XPS)9<>
M;^-M#@*D_4=Q6>J9K7<MT]BE*5^`4KX?>:8;*WW$-H']2U`#\FC;S3C7BMN(
M4WC.]*@1CZT!]TKRJN$)(RJ9'`R4\NI[CN._>LSKS33>]UU"$=]RE`#\T!DI
M6!,V*M_P4R6%/?V!P%7XJ$:\U!>;'K31\6$_'_AMVEF+(:6SE:<`'*59\QD=
MJ`GU*C5J<OYUI>$3Y5L78?"083+)_P`0E6`%E?RSN]?+MS6_>EQF'$MO2&6U
MJ^%*U@$_04!FI2JYZSZOG:8T:[=].382I,9Y"'6G$AT*2H[?(@@@T!8U*53N
M;E(Z^7"P.WR[)M"[9[>B.W)*0VLK2,`CG;R>/G0%Q4JI=<W.\]+S"O:+I-O6
MG79*(\Z+.*5NL!6<.-.``_96<\#C.0ZS,ZCEOV=W1-\FQ)4B.^X&&5_RY`;0
M%I`![*()&?/C-`6U2H/TSU:SU#T(B5XKD:=M,:8EE6Q;+H&"4GRSPH?7Y&LW
M1]R5(Z=66;<9TJ=,F,B2Z](7N5E7D/0#@`?ZF@)E2J#@ZXN47KUXDN3(.EKN
M\[:8:7'?Y8=9V)4I"?++ONY\]WGQ5^4`I7RZXAIM3CJTH0GDJ4<`?>OQAYJ0
MV'&'$.H/92%!0_(H#[I6!R9&:>#+DAE#Q[(4L!1^U:&\.7\:PLR;=*MK=BVK
M$YIX_P`]:L'8$?M^_>@)+2L4B0S&0%2'FVDDX!<4$C]Z^@ZV6@Z'$%LC(7D8
M_-`?=*\W\0A$H'M<?*_@_FI][Z<\UZ:`4K"Q+COK4AA]IQ:/B2A8)'UQ7[(D
ML1DA4EYIE).`7%A()^]`9:K/]0=O>FZ"#S.2(<I#[@`S[N%(S]BL?O5EH6EQ
M`6A04E0R"#D$5Y5NP9Z'HA=CR`I)0XT%A61V((KMC7.BV-J\,XY%7]ZJ5?NC
MB6E7?JCH:\J6MW3,]D1U'/@2RH%OY!0!R/J,_,U'[AT7U%"M$F67H<A]KWA&
MCJ4I2T^>"0.?EYUMX=5Q)I/UZV9"SIN3!O<.WL3G]-\!UC3-QFN)*6Y,D);S
M_4$)P2/N2/L:AMRZ@/3^K,&7*==_@T&9X;+".P'*-^/,G)/KCBOK0_5Q[3>F
ME6J?;S)=C#;%*2&P!SE*_H?,#)\_6O'J?4$K1JX-LTLENWER,W+DR$-I+CRW
M$[L9(.$`$``56QQK'E62LAMSVESQKR_/C7@GO(A\-6JY<1TWQY\+QYWY(?J#
M3<ZU:@N%K0RY*5%=#96RDK!"AE&<=B1Y?4>56'HS1^K[7HR\S;;)]AD2V?>@
MJ9_GN-@*P0<Y03E6.,\5J(VH[I%Z9NW&WS9$6X+O13*?0OWI!6T5`D^6-N,#
MBIWH"5==*]-KAJFY1G[D](W370](PY[.A!(5E6<DX)`]"*]Y^5=71N>N&E[[
M:_A>3QA8U4[M1WRF_;6_OX*>T"FY)UI:DVGQ4S!(2#L!R$Y][</3&<YKL.JV
MG=1(5B5=U3]/2&)\6.)!$9(<2\2@K*?$``!"$[CN\@<9P:L=I?B-(6!C<D*Q
M]:HNHY_QLU+TZTBZP,+X.+CZM[/JE*57$\KO7%RL+^N++:W+0_?=2,-+>CQ$
MD!EA"N%.N%1VCX<`X)]!S4>Z:178'5G65E>@Q(-O?ALR5VR,]XT="E<':"A`
M&X'D;?/N>*F&H]#+G:QB:HLEV7:;PRS[,ZOP`\W(9SG:I)(Y^8/IZ"O'9>GR
MK#K-_5(U'*<?DLE%R]I:;VR,'(4",!L`!(P!V'?N:`BO0?26GY^B[JJ=9X,E
M;UQDL+4ZT%GPTJP$@GX0/08YY[U`);KB^B'46T2"9,*PW=#%N6][ZF4>T(3M
M2H^@S]ED=C4SZ'P;A=](WD6752H;;ERDI<:;9;>+04>%H5W22#G)R..*]G5O
M35JT7T`O=JMJB/$<86IU]8+LETR&RI2C_4K"?P/E0'HUII*QM]$3-BP8T&?"
MMR)K$QA`0\EX)2K=O'O94>"<\YKP7*Y2KPQT6N%P5OER9*7'5XQN46Q[WW[_
M`'J11]#NZJT?9X%QU5)G:;+++G@,--H5(2`"E*W4]T\#L`>.3GD;G4^@S>;W
MIV;$NAMT>Q$*B1&HZ5-Y&!SR.-H``&,"@(S;`BV=<-<R(4=`<%F:D%"$@>(Y
MWR?F2*B_2VS*U;H&3<[KIF%?)]V=>,BX2I:0Z2%$`)RDEL)P,`'YU:5IT4_!
MZA7/5*[RZ^J>UX"XBHZ0A+8QL`5G/&._GS7CM_3^7IZ=,7HV_KM-OF/>.[`>
MB)DM(4?B+65)*,_/(^6,"@*YU<-5:<Z4:9TO?9_A3+A=$6Y^8RZ5*$8DD#=W
MSC`^B<>=>_\`4'HW3MDZ3+7:;/"BO1'66VGFF@ES:5`$%7=6<\Y)YY[U8U[T
M!;;]I1RR7J3.FE;OM/MCKN7D/?WH_I1CL$@!.">.36DU1TWNVJ].BS7_`%?(
M?B(4E0+4)#:G-N,>(<G<>YXV\D<<4!9=5''_`/<_*_\`CP__`%35KQ&W6HK+
M<AX/O)0$K=V[=Y`Y./+/I4`?Z>3AKV=JV+J=YB?(:,<(,-"T-LY!"!D^6T<_
M7UH#5?J=?;1TL?C$;GY<MAEA`Y4I>[=@#S.$FI`J.Y#OG3^,^,.LQGVUCT4&
M$@_]JRLZ`8E7R+=]3W.9?9D-?B1$2`AMB.K^Y+:``3VY5N/`\QFO?>].3+EJ
MRS7EJ\.1FK;NQ$2PE27=_"]RB<\IP!Z=Z`K#5:%])^J+6J(J"G2VH'`Q=$)'
M##Q)(<Q]RK_./,5(-/WU6F_T]6NXLC=+3;&VXJ`,E;Z_<;&/^90J?:KL$+5&
MGIMGNB"N+*;V*QW2>X4/F"`1]*A\SIM(?LNE[9$U'(CQ+$6W&DB,A:7W6SE"
MU@GG'IV\_3`%;Z]L%^/2&W6MK1]QARK"E,P3O;(JL+2"IYS"7"H[B5*X&<XJ
M[.GFHV]6:+M5Y;*=\ED>*D?TNCW5C_,#]L5N;I&<F6Z5&9>\!QYM3:7=@7L)
M&,[3P?H:A_2S0*NG\"5!8O,B?!>7XB&7FPGPE^920?/C(^5`:[K19+U<D6"X
MV6WLWEFU2E/R;0\H!$I)``//!*>2!\^QQ@QRU:VMC6C->W+3=GEV/4<5L2)L
M"0@X:=*-B5I3VQA.3P.V2.:LO4E@F7&YV^YVF[N6Z=#2M`2MLO,.I7C(6WN3
MDC'!!!%>:P:+C09-ZFW:0J[7&\I2W-=>0$(4VE.T-I;'"4X)]2<\F@(IHC0=
MEOW22&W.:2].O,-,F5<5)2N077`%%6]0)RD\#TQ6NU[`;@]7^E2-RGI"$OLN
M27`/%>"$)`*U`<GDGZD^M2NPZ%N6FXR[;I_5$B-9-RE,Q7XJ'W(^XYPVX3VY
M/"DJ_P"^?J_:!=NNJM/7HWR0A=D3B.VXREPK)X65JR"2H`#RQB@*_P!+KDZK
MZHZZD76R1+X;9*]ABQYCR4HBM`K3N2A22/?"02<>1[YK=Z;TA=+#I[7D.ZQ(
MC>G);;DFWP/%\=,<E*RM."``,[2!\JE%XT*?]J7M2Z;N[EENS[8;E_R0]'D@
M`8+C9(Y&.X(/[Y]B]+SW[/=V)>H9;]PN+/LZI);`;81R,-L@[0<%7O'*LGDD
M`"@*WT3HC3T_]/R79-KBKF2+<\^J4MI*G@X`O:H*(R-OEZ?<UJKK>[C+Z3],
MK4[-D(:OTMB%.D)<(<4SOVE.[OR",^H'S-6M8]%.VCIRYI-F\/*3X+D=N864
M[VT+)R,9P2,D`_3TKQQNF4!SI['TE=YCTV/%7OB2D(#+T<@DI4DC(W`D\^8.
M#GS`V,C0-F%PL,NU,IM*[0Z5M^Q-(1XJ"G!;6<9*3Y^M5?HQ+^KM<ZXG7>R0
M]0.1)ZX##,Q](1$925)PA"DJQN`Y/G@_.K3M-@OT<QVKEJM^;'CJ2H!$1#3K
MJ1V#B\G//<@)S^<^"XZ"<:U3*U%I6\.66YS$I3+06!(CR<=E+;)2=WS"A^YR
M!&]+:)U1;M(:UL0<9@Q)WB*LK:)2EF+O"\ME0&0D>YV]2:TF@KG;[-J+2]AU
M=I![3M^AI5&M\R.?\/**D!*LJ!]XJ[X)5S@D@FK+DZ/>GV&ZPKG?KF_,N*4I
M5+:<+/@;3E/A(2<(`/?N5=B2,`8&]&R[C=K5<-3WH7,6MPOPV6(HCH#F,!:_
M>45J'R(&3VH":5KM27--FL%QN2D[Q%86Z$_W$#('YK8U'>HD!RYZ'O<1A*E.
MKC**$I[J4GW@/OC%=*5&5D5+MM'.UM0DX]]'(4V2[-FR)4A6YY]Q3JU>JE')
M/Y-2R-J.S7.TQ(6K;=*>>A-AF--@.);=\(=FUA0*5`=@?3\U#:5]%LIC-)/Q
MVUP82%LH-M>??DD>IM1M7&!%M5I@BWV:*M3C;)<+BW'#P7%J/<X\NP[5<'0Z
M<UJ?0]UTW>0J3&8'@J0I2AN8=!&S<#G@A78\`BN?*E6AM9771BI<BUQXSJ)6
MU"S(;4I.4Y(`PH<\U`S\%78SJK7.]K?OYY^9,PLUU9"ML?'9Z]O''R.C]7G3
M-ALMWE7U.R+<V1%DH"UE<A.PH"$@'(.TD9&/4GSJMY'7A+;VR%8,Q4\)+LG"
MB,<<!)Q^35:Z\UE/UG<(\F>AME+#?AMLM$[$Y.21GS/'X%1BHF%T.J->\A;D
M_P!>%\B5E]8ME/5#U'^?F=8:#ZC6?5ZS'8#D2X)&XQGB,J'F4D?%^Q^536N)
M+9.D6RXQIT-9;DQW$N-J]"#G\5VI`DIF08TE'PO-I<'T(!_UJGZMT^.'-.O\
MLOH6O2\Z65!J?YD9Z_%H2XA2%I"D*&"DC((]#7[2J@M##&B1XN[V:.RSNQN\
M-`3GZXK]D1F)*0F2RT\D'(#B0H`_>LM*`^&6FV6TMLH0VVGLE`P!]J^Z4H!2
ME*`4I2@%5'J^[WNXV;JC$F&"+7;HCC#2$!7B>]&#@.>Q^/G\#U-N5';CHNQW
M"?<IDJ,\7;DP8\M*)+J$/)*-F5("@G=MXW8R!YT!$;UKV[Z8#D.Z6^&_*6S$
M5#,0NK3EYPM;5I"2I6TC/NC*NP`-2?0FH+C?&[@BZVU^(Y%=2EM]41^.W)0I
M.=R4/)"@0<@CGL.>:]UWTM9KP7C<88>\:.F*K*U#W$JWIQ@\*"N0H8(/G6:P
M6"!8FW4P!)4IT@N.29+DAQ6.P*G%$X&3QVYH"(G6\M^QVF28C`5<+T_:5C)P
MA""^-X_XCX(^7)J.])KS?%Q[):6C!3:8NG8LM04%>*K>5IR",8.4?CY]IZ-!
M:>%T$\1'@\F49J4"4[X2'B%!2TM[M@)W*S@<YK[BZ'L,21;7HL5YERWQDQ&/
M#E.I!93DI0L!7O@$DC=GDT!!+1KJ\ITJ9%K@P!&MNGF+NZ)3[KCBP0Z2V%')
M)PT?>43R>0<\;63KF]1)C<6:S9(JYD!-PBNN/N;&TEQ*"VO"<K7EQ&T)`W$X
MX[U*8NB[#%MTF"Q"*8LFWIM;J/&6=T=(6`C).1_O%\CGGOP*^+QHBPW=V([-
MBNEZ(PF/'=:DN-+:2E:5C:I*@00I"3N[\=^30$/&NK_<[7IYRVLP(TN7>WK5
M)\9#@22V'#D)("D@^'R#R.WKC--ZBW5&H)\6!9GIL:W3&X3Z&(4EU;A(07%I
M<0@MIV[\A*CD@=QD9DG_`*?:=%M<@B-*#*YGM^X37_$2_@@N)<W[DDY5G!YW
M'/>LLK0UADW(SG(\A+RP@.I;F/-H?V#"2ZA*@EP@`#*@20`#F@,&J;Y>HVI+
M;9=/Q8#K\R)(D^+,<4E+?A*;`X2"2#XF/W\L5'9O46ZHU!/BP+*],C6^8W"?
M1'AR75N$A!<6EQ""VG;OR$J.2$YR,C-ANVR([=X]S<:S-CLN,-N;C[J%E)4,
M9P<E"?Q6HN&BK'/N[MR?COIDO;2^EF4ZTV^4C`+C:5!*SC`]X'@`'B@*YUWK
M6;*M6I+)*1;G8\FT7!;3L)3J@TIE(!0IQ20A:O>Y"?A(P?*O;-U/<[=8M1.6
M9MA$J-<H$/Q)#KCB2EUN.G(220G_`'F,#`[GD]Y2[TSTL]N#L.4MLI?0EHSG
MRVA+V?$2E&_"0<YP`!G![@5M)&C[)(@W2&[#)CW-;;DE/BK!4I"4)0H'.4D!
MM&",<C/>@(PUK:\,7?\`V:N$."=3KG(0TEC?X*X:LK,CGG"4I6DC/Q@#L16\
MU'?;HWJ.%8-/L0E3WXKDUQZ:I0;;:0I*<!*>5*)4/,8'/H#CTSIER#J:?=)@
M)0RRBWVU*WE/+1''O+4I:LDJ6LG.2>$IK:ZBTS:]0F,NY,N^/&*BS(8?6PZW
MN^()6@A0!P,C.#@>E`0.YW"_6S6.HKA$8MBY473T.3+;<6O:I2%25%#9`['"
ML*/;`X.3@>IURE760+58Y$J#%DM1W6FH<EUU>Y*%+4'$(+:=H7\*CDA).1D9
MG;6E[2TW)0F.LB3!1;GBMY:E+80%A*22<Y_F*][N<\FO"_H/3[TX2S%?0X4H
M0XAJ6\VV\$#:GQ$)4$K(``RH'(`!S0'AT]?KYJ-MVXLQK:SIY3DAA(4XLRB&
MRM&\\;1E:?A\ASG/%:+H7J%V[::M5MB--MQ+7;V&Y"GLI=<=4C(V(.,(`_K/
M"CG'8FIC'T99(UZ7=(K#[$AQ:W5MM2G4L+6H$*66@K85')YQWY[\UEMNDK+;
M'[8_`AEAZW1O8V%H=7GP?[%'/O@$9&[.#R*`WM*UM_OMLT_!,N\3&HK&<`KY
M*CZ)`Y)^0%08]:=*>*M`,_`!(7X'NJ//'?/EZ>=2*L6ZY>JN#:_8X69--3U.
M23*GZV::@:<U4#;7D!N:DR#%`Y8)./\`*3G'I@CTJOW$*;64N)4E0[A0P15E
MZ'A2>H_4UVZ7)&8K2Q)?3G*4I!PAL?@#Z`UTL6FR>4)/U%:6WJCZ?&%$UZY)
M<\Z^S,]5TY9TI70?ICOCC?W.2-&Z"OFJI*!$C+8A'!7+>24MA/\`P_W'Y#]J
MZDTS8XFG;%%M<%/\AE."I0Y63W4?F36UI5'G]2LS6E+B*\%SA=/KQ-M<M^3G
MC]0.E'X=\&H(K),*4E*'U)'#;@&T9]`0!]P?7FH:[AD,-265LR&D.M+&%(6D
M*2H?,&H/+Z3:/DR5/&VJ:*CDH:?6E/V&>/M5G@=<C34JKD^.S17YO1YVVNRI
MKGW.<M&Z<F:HOT>W0D*PI0+KF.&D9Y4?_.378S+:666VFQA"$A*1\AQ6OL%@
MM6GHGLUF@LQ&C\6P94OYJ4>5?<ULZKNI]0>;-:6HKL3^GX/PD7M[;[BE*56%
M@*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*
M4!R+U-U))U+JV<^ZXHQF'%,QF\\(0DXR!ZG&3]?D*BE;_7EFD6'5MS@R4*3A
MY2VU$?&VHDI4/M^^1Y5H*^CXR@J8JOMI:,%D.3MDY]]LL#HEJ)ZR:UC1=W^$
MN2DQG49X*C\!^H4<?]1KJ6N3^C]E>O.O;86T$LPW$RW5^20@Y'Y5@5UA65Z^
MH+(3CWUR:3HCFZ&I=M\"E*51%R*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4
M`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4!'-::-M.KX:6;JTH.MY\*
M0T=KC?T/F/D<BJX1T%B"65+OSYC9X;$8!>/^;=C_`.M*5,HS\C'CZ*YZ1%NP
MJ+I>NR.V6?I33%KTM;S$M#'AI4=SCBCN6X?51_T[5NZ4J+.<IR<I/;9(A",$
1HQ6DA2E*\GH4I2@%*4H#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!3`3@#`2(``A$!`Q$!_\0`
M'0`!``(#`0$!`0````````````8'!`4(`PD!`O_$`#P0``$#`P,"!`4#`@4!
M"0````$"`P0`!1$&$B$',1-!46$(%"(R<15"@1:1(R1B@J$7&%)35G*3E<'2
M_\0`%`$!`````````````````````/_$`!01`0````````````````````#_
MV@`,`P$``A$#$0`_`.J:4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*@NONJ>E]$/?+766X]/V[OE(J/$<`\L\@)_DBMYKV]JTY
MHR\W=H!3L2*MQL*[%>,)S[9(KY_7"9)N,U^9.>6_*?67''5G*E*/<F@[`T_\
M0>C+K,3&E?/VLJ("79;2?#_E25*Q^2`/>K<9=;?:0ZRM#C2P%)6@Y"@>Q!'<
M5\W*ZG^$K4TJ?9+K8):U.-VY2'8RE')2A>[<C\`IR/\`U'TH-!UHZS:ILVO)
MMFT](:@1("DH4?!0XIY12%$G>#@<X`&.W>K+TQU<MW_2^VZHU8M$-Y]Q<<ML
M)*BZXDD$H3WY`S[>M>?5#I]H*^ZEMTO43ST.[SW4L-HBNA*YAX`W)VG.!C*A
MC``R>!7+6L[W)4TC2S$DO6*RRY"814TE"R%+/*R.YX_Y-!VUH?65EUM:US[!
M(4ZTVOPW$+04+;5C."#['OVJ15SC\)5PMD'3NJWI+W@/,.-OR773AM+`2K:<
M^Q#F?XJS=+]8-':EOJ+3;+@Y\VX2EGQF5-I>/HDD=_8X-!8-*4H%*4H%*T^H
MM01K$(:7F)4F3,>\"/'BM[UN+VE6.2`!@$Y40!ZUAV'6-OO%RG6M+$R'>(38
M=>M\IL(="#V4G!*5#L,I41DCUH))2H);>ID&[1YCMFL=_N"83RF)(8C(!:4G
MN/J6-Q]DY/MR,^[_`%*T\WHHZJ9=D2;0A8;>6RWE;"B0G"T$@@Y('\CR.:":
M4J#R^I-LM[<.5=;;>+?:9:DI:N4F,E+&5?;N`45HSZJ2!4>U<E#?Q`:`<8)2
M),>8IW:H[7-K"PDD=B0">:"V:57?3M_3S&IM<JMKET:GIE(D71%Q6-C*E!9&
MSG`3A*CW/&.<``>KO56RMPOU,0;RNP;_``S=TQ/\L#G&>^_;G]VW'EG-!/Z5
M'M2ZPL^G[7$G2WU/)FJ2B&U%3XKDI2AE(;2.^01SVY[U6M^O;EQZU]/C^F76
MTN+3*#S4Q`1XJ0T2CE"E)5CZN,Y&>0,B@N>0^U&CNOR74,L-)*W''%!*4)`R
M22>``/.H_P#U[H__`,UZ?_\`D6?_`-5)"`000"#W!JH?AY@Q5:?U8PJ,RIE.
MHI;:4*0"`D):P,>E!;4=]F2RAZ,ZV\RL92MM04E0]B*UUMU)8[I.<A6R]6R9
M,;!*V(\IMQQ(!P24@DC!(%5:E?\`0O7JVVBTCP+!J**I;D-"L-M2$[SO0GLG
M.U(.,9W'T%1S7&FY=MOFI-=Z51LNUBO>Y]I/9^.8L=2P1^5+)]E*/<"@OB[W
M^SV53*;Q=K?;U/9\(2I*&BYC&=NXC.,CMZBLR9*8A1'I4QYMB,R@K<==4$I0
MD<DDG@"J^O5UM>L+!HF]Q$(>8=N\9UK>`2VKZPI)]P<@^XK8]6WW7M-,V&(3
M\W?Y*+8G`!*6UY+R^?1I*S^<4$NMTZ+<H+$V`^W(B/I"VW6SE*TGS!K(JGOA
MZFR+6W?]#7-9,RP2U!DG]["R2"/YR?PL5<-`I4*'4:UN*>=BP;K)MC,OY)VY
M-,)+"7=P1@94%J&X@;DI(]ZVNI=66ZP2X<%Y,B7=)N?EH$1OQ'G<`DD`D``8
M[J('O02"E0B;JNUWNS:DMDN-=(DJ%%Q.A#8F4TTXC[TE*RD_22>%'&.W8'ST
MO?M-::Z6VB?'ERTV)ME+49<KZWW>2$IVCNHG.$@=O(`4$[I4.@=0(#U\A6FY
M6V[V:7.!,/\`48X0F1@9(2I*E`*_TJP>W&2*_'^H5O1J6?IYBVWB5>8:0M49
MB.#O0<$*"RH(`((Y4H=\=^*"94J.:2UC:]3F>U#$F--MZPB9#F-^&]')SC<.
M1C@\@D<=ZU*^I=I5"EW&%!NLZR1"H/W2.RCY=(3]Q!4L*6!ZH2H4$YI4;OFM
M;/:HUK<#KLYZZ8,"-!1XSLH;=VY`'&W')42`/,U_&G-:6^]WB59U1YUMO,9'
MBN09[00X6\XWI*2I*DY\TJ-!EZYLAU)H^\6=*@A<R,MI"E=DK(^DG^<5\_KG
M`E6NX2(-P87'EQUEMUI8P4J'<5W0GJ-;'5^+&@761:A*$,W-IA*HX=W[,#ZM
MY&[C<$%/O7IKCIMIC6JTO7NW@S$C:)3"BV[CT)'W#\@XH."JZF^$?3KD2PW:
M_O*3MG.)892%9(2WG<3Z9*L<^GO6W_[.6CT6^4RU(NJY3B"&I#[R5%E7D0E*
M4@_@^IKGUF_:IZ5WV^V.U79#3@66'RR4N-E0QA:<Y`5CCU'(/(X"8WQK6&J>
ML%QU+;6$B/9;IX#3TJ0EAAL,KP&]RB/NVY(&?N.>]:C5V@47C6.I9FG[E:XM
MDCS`VJ5<):&&?F%@K6TVL\+VG/IQCCSK&ZKOSIVF-%34.N/VAVWY4Z#N2J<5
MK5(*S_XA403GD_WKS2V['Z"/"Z(6AM^](<M@<!&[#2@ZI/\`IQ@'RS[T%@Z!
MZ3Z>ONB[_"MUY1<-1M`(5,BO.)B(64Y2V.P<3QRK![\=JT'3CHMK%G7EK?NT
M#]/A0)3<EV0MU"PKPU!02@)422<8SV'_`!5A=,XG],?#[*O>FKJGY[PGKD^L
M-)6DN)01X)"AP$[0"?7)'!J2ZIU#K&Q0]4_(KA7!FV1@X);Z0VME0:+A44#A
M8(^D`8P0"<@G`6K2E*!2E*"L.INJKQ`UOI;3-ME,VF)=RLO7-Q*5*2$\E#>[
M*0HC`R0>5IJ/Z?E0$?$@^VQ=%S0W8S&5(?=2HK>\5)*`1@$@$<#L<BKAN]HM
MMZC"/>+?$GQP=P;DLI=2#Z@*!Y]Z\%:>LR?DUHLUN*X/U1,1D`L'O]!Q]//I
M05CT$NMOA6?6@F38S"F=02WG`XZ$E#92@!1SV&4JY]C5>R8[CO1#J=>FVG&K
M5=KPF3!2L%.YKYIO"@#Y'('^VK1Z9=//D(MY1K*PV>4])NCMPCK6A$GPPX$_
M3E2<@@I\N^:WG6'3MQU+T\G6"PL1_&E*:2/$<\-#:4.)7GL?^YC'O01CJ]?+
M2_T6$-J0Q,DW1B.Q!894'%/.%2"-H'IC.?;UK6.1UVKJIT?MD]]"IT.TO,O@
MK!.X1BGG\D$`^>*M#3>F+7`9B356&UP[R&4I>>98;+F[`"O\0)!/;O6V>M=O
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M],QO`^7T]9VBPHK:*(38+:CC)3]/!.!R/04&\6I*$*4M02E(R23@`53GP]W:
MW(T_JIYR=%0TYJ&4ZA2W4I"D%+>%#)[>]7$\VAYI;3R$N-+24J0H9"@>X(\Q
M4:7&TPF]P[6+1;UR)<=V2VI$5LHV-J0E63COEQ/_`#05]%2-?=<X%]M>7M.Z
M>BJ;$U*?\*1(5O!2VKLH#<.1D?3[BIKH27$F7O7++3S+Q%X&]`(5P8D=/(],
MH4/X-3%IMMEM+;*$MMI&$I2,`#V%8T.V0(+BW(4*+'6OA2F6DH*OR0.:#GX6
MJ?T_ZHVO3$="G-,7BZM7&"2>(ZTDA;8XY[@8]-I[YJ;3/$UQU3E)LU^,!&F(
MP:2]&0T\HOOY\3Z5I4,!*`G..^1GN*L"]3;?%N%F8N$<.ORY19BJ+85X;@;6
MYG)^WZ4'D>U&6[/;),=4.)'9=FK+*'(T;[B`5$*4D<#Z3R2!G`[D4%(ZQ:D=
M->K6F]47.^+N#-T"H,]U]III8;PD!12V$@I'TG./V#V%=!!Q);#B5!2"-P4.
M01ZBL6=:K?/<2Y.@1)*TC:%/,I60/3)%93+:&6D-,H2VTA(2E"1@)`[`#R%!
MSU<_F-)6)_6W334ZG+),EJ<599S!*775.E"DM@@*!W?MP#QW-21]\V;XA8MU
MOX^6A7:RB)#==^Q#X4E1:*NP5]*OSN'K5EL:>L'ZJJYL6BU_J05A4I$9OQ0K
MS^O&<UGW&WP[G$7%N42/,C+^YF0VEQ"ORD@B@C^J)=E;M>HRV_;TW']-<7(4
ME2`[X80H)*SWVC)QGUJC+W&==Z(]-;JVX\+=:YK;LUV,`M;"-Y'B`$$93@CD
M'DC(KHF%8+/!MZH$.U0&(*L%4=J.A+:N<\I`P>>:RHT"'%C*CQ8L=F.K.YIM
ML)2<]\@#%!6MUT[8+LYIVYW?6UVN3;,QF3;D^)&(==W`IP&V0I0]<=AD\8S7
MYIN2P[\0^K&VWFU+3:XZ2D*!((*<C^,C^]22&WI*PZCF,0+)#@W%IMA;C\2W
MI"B'W%-H&4)W?<@Y\@.3YU(HUOMJ);DN+$AIE%2@MYMI(7N/W94!G/K04S#9
M>N>O.M,"TNI-PDP66HX0X`2OY=2<`^6%$#V)J3]%[I9I?2FWP)*HS1@LJB7"
M))VI+:P2%AQ*NV>3SZU8+%JM\>6J4Q`B-25$E3R&4I6<]\J`SS6CU#;M,(OM
MJ>NUC@2;E/?,9B0N&VM84&UN<J(R!M0J@J[7J8\7K!I*^&ZO6S3LRW&#$N4'
MPO#9<^LA.5H4A*5)4`#CM[`U-(.F[)!Z@PKU*U+=+I?Q#<9:;=4RL>`,J)4E
MEI.`"HX)[D@<\"I[.@Q)\1<2=%8DQ7!M6R\V%H4/0I/!K&LUBM%C;<19;7!M
MZ'#E8BL):W'WV@9H*'NGS6B;`G5_3/4AD6"7)WBQ2VB0XI;FPI:2<*!W'[0`
M>,Y/:NB&R5(2I2=I(!(/E4:T]"TU=I#E\M]E@MS42'HYE*B-I>WMN*;4=P&>
MZ3SGD5)J##O,HP;/.EI&51V''0/4I23_`/5?.F2^[*DNR)#BG'G5E:UJ.2I1
M.23_`#7T>E,-RHST=Y.YIU!;6/4$8-?/C6FG)FE-33[-<$*#L9PA*B,!Q'[5
MCV(P:#VTOK/4&EFGVK'<EQV'R%.,J;0ZVHCSV+!3GWQFL74VI;QJ>:F7?I[T
MQY"=J-^`E`]$I``2/P!6HI0=+_!Y<7E1M2VU1S';6S(0,=E*"DJY]PA/]JF7
M7;JP="-,6RSMMO7R2CQ,N<HCM\@*(\U$@X'L2?(&C=#]%=6ZBT_$O]JE0H*7
MBHLID.N-.E'8+&U!X//F..>QJ#Z[LUVT_JB7:M0/E^X1@A*W/$4X"DI!3A2N
M2,$4&TD=4=<2)PEN:GN8='[6WMC?_MIPG_BKMZ&];)M\O#&GM7+:<E2/IBSD
MI""M>.$+`XR?(C'/'G7+];32BG4:HLZHQ4'TS&2V4]]V\8Q_-!]$J4I0*4I0
M*4I0*4I0*4I0*4I0>,QD28C["MVUQ"D'8LH/(QP001^15&:`TNS*7I>'*M%X
MCB%:9;,XO"0R!)S'&T*)&4X!("3M.,CD'%\TH*)N+6I)&GM%NW==P3#_`$M2
M)6Z#*DK3*^G!=;86AP*V@X4<@'.1D@U,KPS=V.F=E7XERFS84B$])7X*D2'6
MD/(+A+8)5DH!)3R3S^*L2E!3G@3[]JT2?D[NFVNW[>T7F'F"ADVQ2"H9`4A.
M\D9XY/K6)I"!*B:2T=#@6^\Q9<64MNYH=:?2`L0WA^[@HW;,%/TYQCFKNI04
M[I;2[[R]%M7%F\^#+LKB[J'),@;GTAG8'#N^D@J<PGCSXXJ.2EWIJ'9EO0M0
MBZ6]$!Q4M3<QY;S8?VN)"4?X:<(&5;@5+W'CL:Z%I042W:KA"TKJ.%9X=YC7
M--X6]+4MJ2YXL)4E2AX?U#Q"4$$A"@LC/.2*G'3%B6U9;OXDF6_'<=*XR'H+
M\5+7T`%+:7EJ<*<C/)QDG'%3ZE!1DK3]VA:%TC-0;KXC[;)O8>$J4OAI6S<P
MAQ*]H6K!"2#PG((!K`U#'NPTFS$0W?YDL0Y;T&=\K.;\-05N;:2RE94E7/TK
M>5PE(X.<5T%2@J&]M72;>I$^)%N0$B/8O\0,.-J4!,<+H(P",)5E0/8'G%:1
MEF1I.WW2?:XMR:O\"]O$1Y2G@Q<6GWU(;;2M64*40M*@1DY3]57S6#<;3$N,
MNWR):%+7`>+[`W$)"]I3N(['`4<9[=Z"-3;1>[7TPEP;3+=DZA$5:_F-WUN/
MJRI905=B25;1V'TC@"H@+/:+I<-.Q[/;-1M1F[FE<[YY,MLI_P`K(`)4X<]\
M!12<'(!)S5Q4H*!GPM0MIB,S3<F[%'DW&.T%0Y<LH(D'P2I++B'"/#^Q9*@/
MY2:W+,:0S*B_UNC4USB(M\=%O>C1Y"3XH*O$+J&22ETX0<KXQY]Q5RTH*CT/
M#O%NU(TY>HTY5H=G3TPD--+2F.\J4ZK>^D?<%IQL6?I'^X$VY2JRZS]58O3Z
M(U&C-(F7R2@K984K"6TYQO7CG&<X'G@]L4%FURQ\5M[@W35%LL-NAMOW6*!X
MS[:=SF5_8R,=^^[&/W#'G4-D]<^H#TTR$7I#*=V0RW%:V`>G*2<?DD^]9W0#
MY+4/6)N=J65XD]9<EL!P9#\GOR?+`W*'ND4&R<^&[5I;86S/LYWMI4M+CKB5
M-J(Y3P@@X/&<\^E3C07PY0[=+:F:NGMW%2,*$..DI:*O]2CRH>V$^_I70-*#
M^6FT--H;:0E#:`$I2D8"0.P`JG>OG29S6R&[Q82A-\CM^&II9VIDH'(&?)0R
M<$\'.#CBKDI0<`2>G^KXTM49W3-Y\8';A$-Q8)]E`$'\@U=_0KHK<+;>8^HM
M7LICKC'?%@DA2M_DM>.!CN!WSR<8YZ0I0*4I0*4I0*4I0*4I0*4I0*4I0*4I
M0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*X?^(:1(?ZO7\223X2FFVP?VH#2
M",?WS_-=P50WQ%=*)NIGT:CTTSX]R0@-RHHP%/)'VK3GNH#@CS&,<C!#E*MQ
MHU]^-JZR/PR1(;FLJ;QWW;Q@5AR+5<(TX0I$"6U,/9A;*DN'_:1GR/\`:KXZ
M`]'[F;Y$U)JF(Y"BQ%!V+%?3AQUP?:I23RE*3R,\D@>7<.HJ4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
44I0*4I0*4I0*4I0*4I0*4I0?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
